Although pancreatic ductal adenocarcinoma (PDAC) survival is poor, there are differences in patients' response to the treatments. Detection of predictive biomarkers explaining these differences is of the utmost importance. In a recent study two genetic markers (CD44-rs353630 and CHI3L2-rs684559) were reported to be associated with survival after PDAC resection. We attempted to replicate the associations in 1856 PDAC patients (685 resected with stage I/II) from the PANcreatic Disease ReseArch (PANDoRA) consortium. We also analysed the combined effect of the two genotypes in order to compare our results with what was previously reported. Additional stratified analyses considering TNM stage of the disease and whether the patients received surgery were also performed. We observed no statistically significant associations, except for the heterozygous carriers of CD44-rs353630, who were associated with worse OS (HR = 5.01; 95% CI 1.58-15.88; p = 0.006) among patients with stage I disease. This association is in the opposite direction of those reported previously, suggesting that data obtained in such small subgroups are hardly replicable and should be considered cautiously. The two polymorphisms combined did not show any statistically significant association. Our results suggest that the effect of CD44-rs353630 and CHI3L2-rs684559 cannot be generalized to all PDAC patients.

1st Department of Medicine University of Szeged Szeged Hungary

ARC Net Research Centre University of Verona Verona Italy

Department of Biology University of Pisa Via Derna 1 56126 Pisa Italy

Department of Digestive Tract Diseases Medical University of Lodz Lodz Poland

Department of Gastroenterology and Institute for Digestive Research Lithuanian University of Health Sciences Kaunas Lithuania

Department of General Visceral and Transplantation Surgery University of Heidelberg Heidelberg Germany

Department of Medicine Herlev and Gentofte Hospital Copenhagen University Hospital Herlev Denmark

Department of Medicine Medicina Di Laboratorio University of Padua Padua Italy

Department of Oncology Faculty of Medicine and Dentristry Palacky University Olomouc Olomouc Czech Republic

Department of Oncology Herlev and Gentofte Hospital Copenhagen University Hospital Herlev Denmark

Department of Surgery Erasmus Medical Center Erasmus University Rotterdam The Netherlands

Department of Surgery Gastroenterology Oncology Clinica Chirurgica University of Padua Padua Italy

Department of Surgery Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Department of the Molecular Biology of Cancer Institute of Experimental Medicine Czech Academy of Sciences Prague Czech Republic

Division of Gastroenterology and Research Laboratory Fondazione IRCCS Casa Sollievo Della Sofferenza San Giovanni Rotondo Foggia Italy

Gastroenterology and Gastrointestinal Endoscopy Unit Vita Salute San Raffaele University San Raffaele Scientific Institute Milan Italy

Gastroenterology Unit San Carlo Hospital Potenza Italy

Genomic Epidemiology Group German Cancer Research Center Heidelberg Germany

Institute for Translational Medicine Medical School University of Pécs Pecs Hungary

Laboratory of Biology Medical School National and Kapodistrian University of Athens Athens Greece

Laboratory of Pharmacogenomics Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

National Institute for Health Research Liverpool Pancreas Biomedical Research Unit University of Liverpool Liverpool UK

Pancreato Biliary Endoscopy and Endosonography Division Pancreas Translational and Clinical Research Center IRCCS San Raffaele Scientific Institute Milan Italy

Sant'Andrea Hospital Faculty of Medicine and Psychology Sapienza University of Rome Rome Italy

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. PubMed DOI

Rahib, L. et al. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research vol. 74 2913–2921 (American Association for Cancer Research, 2014). PubMed

Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010;50:545–555. PubMed

Gentiluomo, M. et al. Germline genetic variability in pancreatic cancer risk and prognosis. Semin. Cancer Biol. Online ahead of print (2020). 10.1016/j.semcancer.2020.08.003. PubMed

Signoretti M, et al. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. Unit. Eur. Gastroenterol. J. 2018;6:489–499. doi: 10.1177/2050640617752182. PubMed DOI PMC

Petersen, G. M. et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet.42, 224–8 (2010). PubMed PMC

Low S-K, et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE. 2010;5:e11824. doi: 10.1371/journal.pone.0011824. PubMed DOI PMC

Campa D, et al. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget. 2016;7:57011–57020. doi: 10.18632/oncotarget.10935. PubMed DOI PMC

Campa D, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Dig. Liver Dis. 2013;45:95–99. doi: 10.1016/j.dld.2012.09.014. PubMed DOI

Campa D, et al. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int. J. Cancer. 2015;137:2175–2183. doi: 10.1002/ijc.29590. PubMed DOI PMC

Obazee O, et al. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Int. J. Cancer. 2019;145:686–693. doi: 10.1002/ijc.32127. PubMed DOI

Campa D, et al. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Int. J. Cancer. 2020;147:2065–2074. doi: 10.1002/ijc.33004. PubMed DOI

Corradi C, et al. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Int. J. cancer. 2021 doi: 10.1002/ijc.33475. PubMed DOI

Childs, E. J. et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat. Genet.47, 911–916 (2015). PubMed PMC

Wolpin BM, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat. Genet. 2014;46:994–1000. doi: 10.1038/ng.3052. PubMed DOI PMC

Klein AP, et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat. Commun. 2018;9:556. doi: 10.1038/s41467-018-02942-5. PubMed DOI PMC

Wu C, et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat. Genet. 2011;44:62–66. doi: 10.1038/ng.1020. PubMed DOI

Amundadottir L, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 2009;41:986–990. doi: 10.1038/ng.429. PubMed DOI PMC

Zhang, M. et al. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget.7, 66328–66343 (2016). PubMed PMC

Amundadottir LT. Pancreatic cancer genetics. Int. J. Biol. Sci. 2016;12:314–325. doi: 10.7150/ijbs.15001. PubMed DOI PMC

Galeotti, A. A. et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J. Med. Genet. jmedgenet-2020–106961 (2020). 10.1136/jmedgenet-2020-106961. PubMed

Mohelnikova-Duchonova B, et al. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Sci. Rep. 2017;7:43812. doi: 10.1038/srep43812. PubMed DOI PMC

Tang H, et al. Genetic polymorphisms associated with pancreatic cancer survival: A genome-wide association study. Int. J. Cancer. 2017;141:678–686. doi: 10.1002/ijc.30762. PubMed DOI PMC

Rizzato C, et al. Pancreatic cancer susceptibility loci and their role in survival. PLoS ONE. 2011;6:e27921. doi: 10.1371/journal.pone.0027921. PubMed DOI PMC

Wu C, et al. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut. 2014;63:152–160. doi: 10.1136/gutjnl-2012-303477. PubMed DOI PMC

Rizzato C, et al. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis. 2016;37:957–964. doi: 10.1093/carcin/bgw080. PubMed DOI

Willis JA, et al. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin. Cancer Res. 2012;18:3942–3951. doi: 10.1158/1078-0432.CCR-11-2856. PubMed DOI PMC

Gentiluomo M, et al. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Carcinogenesis. 2019;40:544–550. doi: 10.1093/carcin/bgz006. PubMed DOI

Innocenti F, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin. Cancer Res. 2012;18:577–584. doi: 10.1158/1078-0432.CCR-11-1387. PubMed DOI PMC

Dimitrakopoulos C, et al. Identification and validation of a biomarker signature in patients with resectable pancreatic cancer via genome-wide screening for functional genetic variants. JAMA Surg. 2019;154:e190484. doi: 10.1001/jamasurg.2019.0484. PubMed DOI PMC

Guo Q, et al. Identification of novel genetic markers of breast cancer survival. J. Natl. Cancer Inst. 2015;107:81. doi: 10.1093/jnci/djv081. PubMed DOI PMC

Khan S, et al. Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. Oncotarget. 2018;9:4249–4257. doi: 10.18632/oncotarget.22747. PubMed DOI PMC

Escala-Garcia M, et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br. J. Cancer. 2019;120:647–657. doi: 10.1038/s41416-019-0393-x. PubMed DOI PMC

Ziv E, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat. Commun. 2015;6:7539. doi: 10.1038/ncomms8539. PubMed DOI PMC

Pirie A, et al. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Res. 2015;17:58. doi: 10.1186/s13058-015-0570-7. PubMed DOI PMC

Li W, et al. Genome-wide scan identifies role for AOX1 in prostate cancer survival. Eur. Urol. 2018;74:710–719. doi: 10.1016/j.eururo.2018.06.021. PubMed DOI PMC

Phipps AI, et al. Common genetic variation and survival after colorectal cancer diagnosis: A genome-wide analysis. Carcinogenesis. 2016;37:87–95. doi: 10.1093/carcin/bgv161. PubMed DOI PMC

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 2020;395:2008–2020. doi: 10.1016/S0140-6736(20)30974-0. PubMed DOI

Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol.17, 1471–1474 (2010). PubMed

GTEx Consortium, T. Gte. The genotype-tissue expression (GTEx) project. Nat. Genet.45, 580–5 (2013). PubMed PMC

Boyle AP, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790–1797. doi: 10.1101/gr.137323.112. PubMed DOI PMC

Ward, L. D. & Kellis, M. HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res.40, (2012). PubMed PMC

Genetic Susceptibility in Understanding of Pancreatic Ductal Adenocarcinoma Risk: A Decade-Long Effort of the PANDORA Consortium